BNGO vs. PFE

Last updated Apr 2, 2026

Compare and contrast key facts about Bionano Genomics, Inc. (BNGO) and Pfizer Inc. (PFE).

Performance

BNGO vs. PFE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Bionano Genomics, Inc. (BNGO) and Pfizer Inc. (PFE). The values are adjusted to include any dividend payments, if applicable.

BNGO vs. PFE - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018
BNGO Bionano Genomics, Inc.	-22.22%	-91.16%	-84.74%	-87.05%	-51.17%	-2.92%	148.39%	-76.34%	-25.04%
PFE Pfizer Inc.	16.58%	0.65%	-2.22%	-41.26%	-10.41%	66.70%	3.07%	-6.91%	-0.17%

Fundamentals

EPS BNGO : -$9.02 PFE : $1.36
PS Ratio BNGO : 0.12 PFE : 2.60
Total Revenue (TTM) BNGO : $28.51M PFE : $62.58B
Gross Profit (TTM) BNGO : $13.51M PFE : $44.01B
EBITDA (TTM) BNGO : -$19.47M PFE : $15.10B

Returns By Period

In the year-to-date period, BNGO achieves a -22.22% return, which is significantly lower than PFE's 16.58% return.

BNGO

• 1D: 1.71%
• 1M: 4.39%
• YTD: -22.22%
• 6M: -31.61%
• 1Y: -61.61%
• 3Y*: -87.87%
• 5Y*: -80.91%
• 10Y*: —

PFE

• 1D: 1.67%
• 1M: 4.73%
• YTD: 16.58%
• 6M: 8.56%
• 1Y: 24.79%
• 3Y*: -5.70%
• 5Y*: 0.19%
• 10Y*: 4.49%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

BNGO vs. PFE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BNGO

BNGO Risk / Return Rank: 15
BNGO Sharpe Ratio Rank: 13
BNGO Sortino Ratio Rank: 15
BNGO Omega Ratio Rank: 13
BNGO Calmar Ratio Rank: 15
BNGO Martin Ratio Rank: 21

PFE

PFE Risk / Return Rank: 69
PFE Sharpe Ratio Rank: 72
PFE Sortino Ratio Rank: 66
PFE Omega Ratio Rank: 63
PFE Calmar Ratio Rank: 72
PFE Martin Ratio Rank: 71

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BNGO vs. PFE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Bionano Genomics, Inc. (BNGO) and Pfizer Inc. (PFE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	BNGO	PFE	Difference
Sharpe ratio Return per unit of total volatility	-0.64	0.94	-1.58
Sortino ratio Return per unit of downside risk	-0.74	1.46	-2.20
Omega ratio Gain probability vs. loss probability	0.89	1.18	-0.29
Calmar ratio Return relative to maximum drawdown	-0.74	1.66	-2.39
Martin ratio Return relative to average drawdown	-1.06	3.73	-4.80
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

BNGO vs. PFE - Sharpe Ratio Comparison

The current BNGO Sharpe Ratio is -0.64, which is lower than the PFE Sharpe Ratio of 0.94. The chart below compares the historical Sharpe Ratios of BNGO and PFE, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	BNGO	PFE	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.64	0.94	-1.58
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.88	0.01	-0.88
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.19	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.34	0.27	-0.61

Correlation

The correlation between BNGO and PFE is 0.13, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

BNGO vs. PFE - Dividend Comparison

BNGO has not paid dividends to shareholders, while PFE's dividend yield for the trailing twelve months is around 6.02%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
BNGO Bionano Genomics, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
PFE Pfizer Inc.	6.02%	6.91%	6.33%	5.70%	3.12%	2.64%	3.92%	3.68%	3.12%	3.53%	3.69%	3.47%

Drawdowns

BNGO vs. PFE - Drawdown Comparison

The maximum BNGO drawdown since its inception was -99.99%, which is greater than PFE's maximum drawdown of -58.96%. Use the drawdown chart below to compare losses from any high point for BNGO and PFE.

Drawdown Indicators

	BNGO	PFE	Difference
Max Drawdown Largest peak-to-trough decline	-99.99%	-58.96%	-41.03%
Max Drawdown (1Y) Largest decline over 1 year	-77.85%	-12.59%	-65.26%
Max Drawdown (5Y) Largest decline over 5 years	-99.98%	-58.96%	-41.02%
Max Drawdown (10Y) Largest decline over 10 years	—	-58.96%	—
Current Drawdown Current decline from peak	-99.99%	-41.79%	-58.20%
Average Drawdown Average peak-to-trough decline	-83.33%	-17.33%	-66.00%
Ulcer Index Depth and duration of drawdowns from previous peaks	53.86%	5.58%	+48.28%

Volatility

BNGO vs. PFE - Volatility Comparison

Bionano Genomics, Inc. (BNGO) has a higher volatility of 33.96% compared to Pfizer Inc. (PFE) at 6.30%. This indicates that BNGO's price experiences larger fluctuations and is considered to be riskier than PFE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BNGO	PFE	Difference
Volatility (1M) Calculated over the trailing 1-month period	33.96%	6.30%	+27.66%
Volatility (6M) Calculated over the trailing 6-month period	49.48%	17.39%	+32.09%
Volatility (1Y) Calculated over the trailing 1-year period	97.14%	26.78%	+70.36%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	92.44%	25.47%	+66.97%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	193.73%	23.90%	+169.83%

Financials